JOHN HOPE FRANKLIN CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1838-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.duke.edu
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00006474
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00016991
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Phase 2
Completed
- Conditions
- Brain and Central Nervous System TumorsNeuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005955
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Phase 1
Completed
- Conditions
- Brain and Central Nervous System TumorsChildhood Germ Cell TumorHead and Neck CancerKidney CancerNeuroblastomaOvarian CancerSarcomaTesticular Germ Cell Tumor
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT00005952
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide in Treating Patients With Brain Metastases
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005954
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT00003462
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 36
- Registration Number
- NCT00002986
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer
Not Applicable
Completed
- Conditions
- Breast CancerDepressionMalnutritionProstate CancerFatiguePsychosocial Effects of Cancer and Its Treatment
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Duke University
- Registration Number
- NCT00037024
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer
Not Applicable
Completed
- Conditions
- Prostate CancerMalnutrition
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Duke University
- Registration Number
- NCT00044980
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005951
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath